Qian Qian Guo’s research while affiliated with First Affiliated Hospital of China Medical University and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (1)


Figure 3. Comparisons of cumulative incidence rates of SHNCs of different pathological origins between patients who received RT and those who did not. (a) Cumulative incidences of SHNC originated from ESCC. (b) Cumulative incidences of SHNC originated from EAC. (c) Cumulative incidences of secondary HNSCC originated from ESCC. EAC: esophageal adenocarcinoma; EC: esophageal cancer; ESCC: esophageal squamous cell cancer; HNSCC: head and neck squamous cell cancer; NRT: no radiation therapy; RT: radiotherapy; SHNC: secondary head and neck cancer.
Figure 5. Dynamic standardized incidence ratio of SHNC. (a) Year of EC diagnosis. (b) Age at EC diagnosis (years). (c) Latency after EC diagnosis (months). EC: esophageal cancer; NRT: no radiation therapy; RT: radiotherapy.
Figure 6. Comparison of overall survival between EC patients who developed SHNC after RT and NRT. EC: esophageal cancer; NRT: no radiation therapy; RT: radiotherapy; SHNC: secondary head and neck cancer.
Figure 7. Comparison of overall survival between EC patients who developed SHNC and matched only primary HNC. (a) SHNC after RT and matched only primary HNC. (b) SHNC after NRT and matched only primary HNC. EC: esophageal cancer; NRT: no radiation therapy; RT: radiotherapy; SHNC: secondary head and neck cancer.
Baseline Characteristics of EC Patients Who Experienced SHNC Categorized by Therapeutic Modalities Including RT and NRT

+1

Association of Definitive Radiotherapy for Esophageal Cancer and the Incidence of Secondary Head and Neck Cancers: A SEER Population-Based Study
  • Article
  • Full-text available

June 2024

·

29 Reads

·

1 Citation

World Journal of Oncology

Qian Qian Guo

·

Shi Zhou Ma

·

De Yao Zhao

·

[...]

·

Background Impact of radiotherapy (RT) for esophageal cancer (EC) patients on the development of secondary head and neck cancer (SHNC) remains equivocal. The objective of this study was to investigate the link between definitive RT used for EC treatment and subsequent SHNC. Methods This study was conducted using the Surveillance, Epidemiology, and End Results (SEER) database to collect the data of primary EC patients. Fine-Gray competing risk regression and standardized incidence ratio (SIR) and propensity score matching (PSM) method were used to match SHNC patients with only primary head and neck cancer (HNC) patients. Overall survival (OS) rates were applied by Kaplan-Meier analysis. Results In total, 14,158 EC patients from the SEER database were included, of which 9,239 patients (65.3%) received RT and 4,919 patients (34.7%) received no radiation therapy (NRT). After a 12-month latency period, 110 patients (1.2%) in the RT group and 36 patients (0.7%) in the NRT group experienced the development of SHNC. In individuals with primary EC, there was an increased incidence of SHNC compared to the general US population (SIR = 5.95, 95% confidence interval (CI): 5.15 - 6.84). Specifically, the SIR for SHNC was 8.04 (95% CI: 6.78 - 9.47) in the RT group and 3.51 (95% CI: 2.64 - 4.58) in the NRT group. Patients who developed SHNC after RT exhibited significantly lower OS compared to those after NRT. Following PSM, the OS of patients who developed SHNC after RT remained significantly lower than that of matched patients with only primary HNC. Conclusion An association was discovered between RT for EC and increased long-term risk of SHNC. This work enables radiation oncologists to implement mitigation strategies to reduce the long-term risk of SHNC in patients who have received RT following primary EC.

Download

Citations (1)


... miRNA-145-5p acting as both an oncogene and a tumour suppressor Esophageal cancer. Esophageal cancer ranks seventh among cancers worldwide; it has a high mortality with an estimated 544,000 esophageal cancer deaths in 2020 (85). Fan et al (40) found that miRNA-145-5p was negatively related to ABRA C-terminal like (ABRACL). ...

Reference:

Role of miRNA‑145‑5p in cancer (Review)
Association of Definitive Radiotherapy for Esophageal Cancer and the Incidence of Secondary Head and Neck Cancers: A SEER Population-Based Study

World Journal of Oncology